High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

Phase 3 Completed 15 enrolled M.D. Anderson Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors. The safety of this treatment will also be studied.

Timeline

Start: 2001-11
Primary completion: 2005-01
Completion: 2005-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	131I-MIBG	Protein / enzyme biologic	—	Intravenous

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

Summary

Timeline

Drugs

Indications